In a post on X.com, Neuralink said it had been granted regulatory approval for "a new feasibility trial to extend BCI control ...

Erin Taylor, a disability advocate and botany enthusiast with ALS, used the technology to introduce herself and then welcome ...

A biotech start-up that has shown the ability to pause and in some cases reverse neurodegenerative diseases in mice has ...

Study failed to meet primary and secondary efficacy endpoints - WARREN, N.J., Nov. 26, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced ...

Sydney, Australia, 28 November 2024 – Celosia Therapeutics, an Australian biotech company developing advanced gene therapies for neurodegenerative diseases, has completed one of the largest Series A ...

We recently published a list of 10 Cheapest Stocks to Buy On Robinhood. In this article, we are going to take a look at where ...

Since Jimmer Szatkowski opened Upstate New York’s first Chick-fil-A in 2018, he’s been at the restaurant most every day. He’s ...

Sydney-based biotechnology company Celosia Therapeutics has secured $16.75 million in Series A funding to advance its ...

LYON, France I6, 2024 I MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of ...

Explore some of the most influential disabled names in history and discover how they overcame adversity to change the world ...

PTC Therapeutics’ phase 2 CardinALS study of utreloxastat in ALS patients fails to meet primary endpoint: Warren, New Jersey Thursday, November 28, 2024, 15:00 Hrs [IST] PTC The ...

Thompson, who has spent the latter part of his coaching career battling ALS, is more than a great football coach. He is a ...